Immune response of hepatitis B immunization in pediatric cancer survivors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20201021003

Enrollment

107

Registered

2020-10-21

Start date

2018-04-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The study is an observational study and aims to evaluate the immune response to hepatitis B immunization in pediatric cancer survivors at Phramongkutklao hospital hepatitis b virus, immune response, immunization, pediatric, cancer

Interventions

Pediatric cancer survivor patients treated at Phramongkutklao hospital between 2016&#45

2018

Diagnostic

Pediatric cancer survivor patients

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria include patients less than 18 years of age who were diagnosed with cancer at Phramongkutklao hospital and completed chemotherapy for at least 6 months

Exclusion criteria

Exclusion criteria: Patients who had underlying primary immunodeficiency or on immunosuppressive drugs

Design outcomes

Primary

Measure	Time frame
Immune response to hepatitis B immunization 2 years Anti-HBs, Anti-HBc and HBsAg using mean with standard deviation for continuous variables	—

Secondary

Measure	Time frame
Correlation of immune response to hepatitis B immunization and chemotherapy regimens 2 years Independent T-test	—

Countries

Thailand

Contacts

Public ContactPiya Rujkijyanont

Phramongkutklao Hospital and College of Medicine

piya_rujk@yahoo.com0910034585

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026